Google
CPRX — CATALYST PHARMACEUTICALS INC (Healthcare >> Biotechnology)
CPRX FAQ
What is CPRX's P/E ratio?
CATALYST PHARMACEUTICALS INC (CPRX) currently trades at a P/E ratio of 17.29.
What is CPRX's ROE?
CATALYST PHARMACEUTICALS INC reports a Return on Equity (ROE) of 21.85%.
What is CPRX's dividend yield?
CATALYST PHARMACEUTICALS INC offers a dividend yield of 0.00%.
What is CPRX's Deepscope Quality Score?
Deepscope rates CPRX's overall financial quality at 85 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy CPRX?
Deepscope's AI Timing Score for CPRX is 91 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does CPRX belong to?
CATALYST PHARMACEUTICALS INC is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange.
|
USD 31.28
Price
0.01
(0.03%)
Day Change
|
|
|---|
CPRX, ファンダメンタルスコアはvery good ( ファンダメンタル = 85) そして テクニカルスコアは ...(Sign In to See)...
Loading chart...
- Signal
- OUTPERFORM
- Signal Description
- Company financial health is Good
- Reason
-
ROEの伸びが低い
ROAの伸びが低い
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Lorem ipsum dolor sit amet
In details, quality factors are not quite good , financial health is not good , and ability to make profit is good , ...
| Deepscope 分析 |
|
54% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 1.51 From 30 days period |
| News Score | 99 |
| Magic Formula Rank by ROA |
522
|
| Magic Formula Rank by ROE |
522
|
| Magic Formula Rank by ROIC |
450
|
| Price | 31.28 |
| PBV / Sector |
3.78 / 4.48
|
| Earning Per Share | 1.81 |
| PE / Sector |
17.29 / 16.68
|
| PEG or PE/Growth / Sector |
0.43 / 0.53
GOOD
|
| Average 1M Daily Value |
97.01 M
|
| Average 1W Daily Value |
56.53 M
|
| Timing Factors |
|
71% |
| Financial Health |
|
41% |
| ポイントになる統計 |
|
77% |
| 配当 |
|
4% |
| 登録情報 |
| Analyze Date | 2026-06-04 09:24:22 |
| Symbol | CPRX |
| Name | CATALYST PHARMACEUTICALS INC |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 122.38 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 3,826.85 / 8,483.11 |
| ニュース |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 355 Alhambra Circle, Coral Gables, FL, United States, 33134
Phone: 305 420 3200
Website: https://catalystpharma.com
Employees: 182
Sector: Healthcare >> Biotechnology
Description: Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing medicines for patients living with rare diseases in the United States. It offers Firdapse for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); Fycompa, a novel non-competitive selective antagonist at the postsynaptic ionotropic alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid glutamate receptor that is used to treat focal onset seizures, as well as tonic-clonic seizure; and AGAMREE, a corticosteroid for the treatment of duchenne muscular dystrophy. The company has license agreements with BioMarin Pharmaceutical Inc.; and a collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. Catalyst Pharmaceuticals, Inc. was founded in 2002 and is based in Coral Gables, Florida.
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
